SCHEMBL30120959

SCHEMBL30120959

Cc1nc2cc(O)ccc2c(Cl)c1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
ALOX15 P16050 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ESR1 P03372 4/20 0.35
MPO P05164 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE2A O00408 3/20 0.35
PDE10A Q9Y233 3/20 0.35
ESR2 Q92731 3/20 0.35
HSD17B3 P37058 1/20 0.35
ERAP1 Q9NZ08 1/20 0.35
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887701 1.00 TRPV1 (0.37) TRPV1KDM4EMAPTALOX15ALDH1A1
SCHEMBL25544331 0.84 ALDH1A1 (0.39) KDM4EMAPTALDH1A1KMT2A
SCHEMBL23887808 0.79 MPO (0.47) KDM4EMAPTALDH1A1GAAHPGD
SCHEMBL7125134 0.77 MAOA (0.53) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL23896383 0.77 ESR1 (0.55) KDM4EMAPTALDH1A1GAAESR1
SCHEMBL30121085 0.77 ESR1 (0.55) KDM4EMAPTALDH1A1GAAESR1
SCHEMBL23887859 0.75 KDM4E (0.42) KDM4EMAPTESR1ESR2
SCHEMBL30121046 0.75 KDM4E (0.42) KDM4EMAPTESR1ESR2
SCHEMBL30367341 0.74 MPO (0.34) KDM4EMAPTALDH1A1GAAHPGD
SCHEMBL28974954 0.74 MPO (0.34) KDM4EMAPTALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126819-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) Vertex Pharmaceuticals Incorporated (US) 2023-02-08 EP disclosed